// App-Quantinova.ai

TPS3131 : A phase 1/2 study with birinapant in combination with pembrolizumab.

Researchers

Presenter

  • Russell J. Schilder

Principal Investigators

  • Mark Albertella

  • James Strauss

  • Malin Sydvander

  • Santosh M. Nair

  • Kingsley Urakpo

  • Stefan Norin

  • John Ohd

Medical Centers

  • Thomas Jefferson University, Philadelphia, PA

  • Medivir AB, Huddinge, Sweden

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Mid Florida Hem Onc Ctr, Sanford, FL

Locations

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • birinapant

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT02587962

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved